Investment analysts at Barclays initiated coverage on shares of Gossamer Bio (NASDAQ:GOSS – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. Get Gossamer Bio alerts:View Our Latest Stock Analysis on GOSSGossamer Bio Stock PerformanceGossamer Bio stock traded down $0.05 during mid-day trading on Tuesday, reaching $2.51. Gossamer Bio Company Profile(Get Free Report)Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need. Featured ArticlesReceive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.